查看購物車
  • English
  • Japanese
封面
市場調查報告書
商品編碼
2018693

核酸增幅檢查市場：依技術、產品類型、最終用戶和應用分類－2026-2032年全球市場預測

Nucleic Acid Amplification Testing Market by Technology, Product Type, End User, Application - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 185 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2025 年，核酸增幅檢查市場價值將達到 40 億美元，到 2026 年將成長至 45.4 億美元，年複合成長率為 13.20%，到 2032 年將達到 95.4 億美元。

主要市場統計數據
基準年 2025 40億美元
預計年份：2026年 45.4億美元
預測年份 2032 95.4億美元
複合年成長率 (%) 13.20%

為核酸增幅檢查，這對於臨床醫學和公共衛生領域的診斷和調查至關重要。

核酸增幅檢查(NAAT) 曾經是檢查室的專業技術，但如今已成為現代診斷、研究和臨床決策的基石。分子生物學、儀器和軟體的進步拓展了擴增檢測的應用範圍和方法，使得在臨床、公共衛生和研究領域能夠更快、更準確地檢測遺傳物質。本文概述了塑造當前局面的技術基礎、市場促進因素和營運背景，並重點探討了創新與推廣應用障礙之間的相互作用。

重構核酸增幅檢查，並確定影響其應用和商業化的關鍵技術和操作轉折點。

核酸增幅檢查的現狀正經歷著一場變革，其驅動力包括技術融合、檢測分散化以及人們對快速、可操作結果日益成長的需求。這種融合在先進化學技術數位資料分析的整合中尤其明顯，數位PCR平台和即時PCR儀如今與成熟的等溫PCR方法並存，簡化了工作流程。雖然這種變化使得核酸擴增檢測能夠在非常規環境中得到更廣泛的應用，但也帶來了新的性能權衡和監管方面的考慮。

我們評估了近期關稅趨勢如何對整個 NAAT 價值鏈的採購、在地化生產、定價策略和創新時間表施加多方面的壓力。

2025年實施的新關稅措施和貿易政策變化迫使核酸增幅檢查系統中的相關人員在其採購、定價和供應連續性策略中全面考慮這些因素。儀器、試劑和配件的關稅可能會推高接收成本，並擠壓經銷商和服務供應商的利潤空間，促使許多買家重新評估其供應商組合和庫存策略。為此，一些製造商和檢測實驗室正在轉向雙重採購、確保替代供應管道並建立緩衝庫存，以降低短期供應中斷的風險。

我們提供有關技術、產品、最終用戶和應用的詳細見解，闡明效能權衡和商業化途徑。

核酸增幅檢查策略規劃的核心在於技術選擇，目前市場對等溫擴增及聚合酵素鏈鎖反應(PCR) 平台均有廣泛的探討。等溫擴增方法包括多種變體，例如解旋酶依賴性擴增、環介導擴增、核酸序列擴增、鏈置換擴增和轉錄媒介增幅，每種方法在速度、儀器簡易性和溫度控制方面都各具優勢。相較之下，聚合酵素鏈鎖反應(PCR) 技術則根據其模式進行區分：數位 PCR 和即時PCR 。數位平台強調絕對定量和靈敏度，而即時系統則專注於臨床工作流程中的通量和動態數據。

本文說明了區域法規結構、投資趨勢和製造能力如何在全球主要地區形成不同的採用路徑。

區域趨勢正在影響美洲、歐洲、中東和非洲以及亞太地區的投資重點、監管方式和經營模式，每個地區都呈現出獨特的機會和營運考量。在美洲，由於醫療網路一體化和報銷機製成熟，對高通量檢測系統和照護現場能力的需求持續旺盛。同時，監管路徑強調對臨床效用的嚴格檢驗和論證。該地區在應對疫情和基因組監測方面也獲得了大量的公共和私人投資，從而推動了各種核酸擴增檢測（NAAT）技術的廣泛應用。

我們將檢驗策略經營模式、夥伴關係生態系統和營運投資，這些模式和投資使公司能夠在設備、試劑和資訊服務。

核酸增幅檢查領域的企業策略體現了技術創新、營運韌性和商業性規模之間的平衡。主要企業正投資於整合型產品組合，將強大的儀器平台與專有試劑和數據分析能力相結合，以確保永續的收入來源和競爭優勢。同時，一些企業正專注於模組化或開放平台方案，利用第三方試劑和檢測開發合作夥伴，加速在不同終端用戶環境中的部署。

為了推動永續成長，我們制定了技術發展、供應鏈多元化、監管合作和服務主導商業化的高優先級策略行動。

產業領導企業應採取多管齊下的策略，使其技術藍圖與供應鏈韌性和以客戶為中心的商業化相契合。優先開發模組化平台，以支援集中式高吞吐量需求和分散式照護現場部署，從而使單一產品系列能夠利用通用耗材和檢驗的工作流程滿足多種終端用戶需求。這種方法可以降低客戶的複雜性，並加速在所有環境中的部署。

概述一項混合方法研究，該研究結合了專家訪談、技術審查和情境分析，以檢驗核酸增幅檢查。

本分析的調查方法結合了結構化的初步調查、有針對性的二次調查以及嚴格的檢驗，以確保其相關性和準確性。初步調查包括對臨床實驗室主任、醫院採購負責人、檢測開發人員和技術供應商的詳細訪談，以收集有關推廣應用促進因素、營運障礙和採購趨勢的實際見解。此外，還與分子生物學家和生物資訊學專家進行了技術諮詢，以評估檢測性能方面的權衡取捨和整合挑戰，從而補充了這些定性資訊。

本報告總結了技術進步、營運韌性和政策因素的融合，這些因素共同塑造了核酸增幅檢查的長期應用和價值創造。

總之，核酸增幅檢查正處於一個策略轉折點，技術創新、商業策略和政策動態在此交匯，共同塑造其未來發展方向。等溫和先進PCR技術的成熟、攜帶式和台式平台的普及以及複雜數據分析工具的整合，正在拓展其應用範圍和應用環境。同時，貿易政策、監管預期和區域製造地的變化，要求相關人員在採購、檢驗和市場准入方面做出謹慎的決策。

目錄

第1章：序言

第2章：調查方法

  • 調查設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查的前提
  • 研究限制

第3章執行摘要

  • 首席體驗長觀點
  • 市場規模和成長趨勢
  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 波特五力分析
  • PESTEL 分析
  • 市場展望
  • 上市策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會映射
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：美國關稅的累積影響，2025年

第7章：人工智慧的累積影響，2025年

第8章：核酸增幅檢查市場：依技術分類

  • 等溫擴增
    • 解旋酶依賴性擴增
    • 環介導擴增
    • 基於核酸序列的擴增
    • 鏈取代擴增
    • 轉錄媒介增幅
  • 聚合酵素鏈鎖反應
    • 數位聚合酵素鏈鎖反應
    • 即時聚合酵素鏈鎖反應

第9章：核酸增幅檢查市場：依產品類型分類

  • 裝置
    • 桌面設備
    • 可攜式設備
  • 試劑和試劑盒
    • 緩衝溶液
    • 酵素
    • 母帶混音
    • 引子和探針
  • 軟體服務
    • 數據分析軟體
    • 維護和支援
    • 培訓和諮詢服務

第10章：核酸增幅檢查市場：依最終用戶分類

  • 診斷檢查室
  • 醫院
  • 即時檢測
  • 研究機構

第11章：核酸增幅檢查市場：依應用領域分類

  • 伴隨診斷
  • 基因檢測
    • 攜帶者篩檢
    • 產前基因檢測
    • 罕見疾病的診斷
  • 感染疾病
    • 細菌感染疾病
    • 寄生蟲感染疾病
    • 性行為感染
  • 腫瘤學
    • 生物標記檢測
    • 微量殘存疾病的檢測
    • 突變分析

第12章：核酸增幅檢查市場：依地區分類

  • 北美洲和南美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第13章：核酸增幅檢查市場：依組別分類

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第14章：核酸增幅檢查市場：依國家分類

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第15章：美國核酸增幅檢查市場

第16章：中國核酸增幅檢查市場

第17章 競爭格局

  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年
  • Abbott Laboratories
  • Becton, Dickinson and Company
  • BGI Genomics Co. Ltd.
  • Bio-Rad Laboratories, Inc.
  • bioMerieux SA
  • Bruker Corporation
  • Danaher Corporation
  • Diasorin SpA
  • F. Hoffmann-La Roche AG
  • Grifols, SA
  • Hologic, Inc.
  • Molbio Diagnostics Pvt. Ltd.
  • Mylab Discovery Solutions
  • Pfizer Inc
  • QuidelOrtho Corporation
  • Randox Laboratories Ltd
  • Thermo Fisher Scientific Inc.
Product Code: MRR-AD36CD897FB8

The Nucleic Acid Amplification Testing Market was valued at USD 4.00 billion in 2025 and is projected to grow to USD 4.54 billion in 2026, with a CAGR of 13.20%, reaching USD 9.54 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 4.00 billion
Estimated Year [2026] USD 4.54 billion
Forecast Year [2032] USD 9.54 billion
CAGR (%) 13.20%

Establishing the foundational context for nucleic acid amplification testing as an essential diagnostic and research enabler across clinical and public health environments

Nucleic acid amplification testing (NAAT) has evolved from a laboratory specialty into a cornerstone of modern diagnostics, research, and point-of-care decision-making. Advances in molecular biology, instrumentation, and software have expanded where and how amplification assays are deployed, enabling faster, more accurate detection of genetic material across clinical, public health and research settings. This introduction frames the technological foundations, market drivers, and operational contexts that shape the current landscape while highlighting the interplay between innovation and adoption barriers.

Rapid polymerase chain reaction (PCR) workflows and diversified isothermal approaches have broadened assay capability beyond centralized laboratories, empowering clinicians with actionable data at the bedside and supporting large-scale surveillance programs. At the same time, reagent chemistry optimization, miniaturized benchtop and portable instruments, and improvements in data analysis pipelines have driven throughput gains and permitted more complex multiplexing strategies. These developments are accompanied by evolving regulatory expectations and quality requirements that determine how assays transition from development to routine use.

Taken together, NAAT is positioned at the nexus of clinical need, regulatory rigor and technological possibility. Understanding the current state requires evaluating the full value chain from assay chemistry and instrument design through to software and service delivery, and this report's introduction grounds subsequent analyses in those practical realities.

Identifying the major technological and operational inflection points reshaping nucleic acid amplification testing with implications for adoption and commercialization

The landscape of nucleic acid amplification testing is undergoing transformative shifts driven by technology convergence, decentralization of testing, and heightened expectations for rapid, actionable results. Convergence is evident in the integration of advanced chemistry with digital data analysis, where digital PCR platforms and real-time PCR instruments now coexist alongside a maturing suite of isothermal methods that facilitate simplified workflows. This shift enables broader adoption in non-traditional settings while also introducing new performance trade-offs and regulatory considerations.

Decentralization has accelerated as portable and benchtop instruments become more reliable and user-friendly, enabling point-of-care applications in emergency medicine, outpatient clinics and field use for infectious disease surveillance. Simultaneously, reagent innovation-including master mixes, optimized enzymes and stabilized buffers-has reduced cold-chain dependencies and extended assay lifetimes, supporting mobile deployments. The rise of cloud-native data analysis and laboratory information management integrations is enhancing throughput and traceability, while also raising new data governance and cybersecurity requirements.

Finally, strategic shifts among stakeholders, including vertical integration by product manufacturers and increased collaboration between diagnostics developers and service providers, are reshaping go-to-market dynamics. These changes collectively redefine how tests are developed, validated and delivered, and they create both opportunities and new operational complexities for laboratories, health systems and commercial players.

Assessing how recent tariff developments exert multifaceted pressure on sourcing, manufacturing localization, pricing strategies and innovation timelines across the NAAT value chain

The imposition of new tariff measures and trade policy changes in 2025 has created a cumulative set of considerations that stakeholders in the nucleic acid amplification testing ecosystem must now factor into sourcing, pricing and supply continuity strategies. Tariffs that target instruments, reagents and ancillary components escalate landed costs and can compress margins for distributors and service providers, prompting many buyers to reassess supplier portfolios and inventory strategies. In response, some manufacturers and laboratories are moving toward dual-sourcing, qualifying alternative supply lines, and building buffered inventory to mitigate short-term disruption risk.

Beyond direct cost implications, tariffs influence longer-term strategic decisions such as localization of production, contractual rebalancing with tier-one suppliers, and increased scrutiny of value chain transparency. Firms that previously relied heavily on single-country manufacturing may accelerate plans to diversify production footprints or to enter co-manufacturing partnerships to preserve market access while controlling costs. Regulatory approvals and quality management systems add complexity to these moves, because relocating production requires sustained investment in compliance and validation.

Moreover, tariffs have knock-on effects on innovation timelines and capital allocation, as higher import costs can deter investment in new instrument lines or reagent chemistries that are capital-intensive. For organizations that operate across borders, harmonizing procurement policies and updating cost modeling to reflect tariff scenarios is essential. Adopting scenario-based financial planning and strengthening relationships with logistics and customs specialists will help stakeholders navigate the cumulative impacts of trade policy shifts in 2025 and beyond.

Delivering nuanced insights across technology, product, end user and application dimensions to clarify performance trade-offs and commercialization pathways

Technology choices are central to strategic planning in nucleic acid amplification testing, with the market broadly studied across isothermal amplification and polymerase chain reaction platforms. Isothermal methods encompass variants such as helicase dependent amplification, loop mediated amplification, nucleic acid sequence based amplification, strand displacement amplification and transcription mediated amplification, each offering distinct advantages in speed, equipment simplicity and temperature control. In contrast, polymerase chain reaction techniques are differentiated by digital PCR and real-time PCR modalities, with digital platforms emphasizing absolute quantification and sensitivity while real-time systems focus on throughput and kinetic data for clinical workflows.

Product type segmentation highlights that instrument platforms, reagents and kits, and software and services form mutually reinforcing pillars of capability. Instruments are available in benchtop and portable formats to suit laboratory and point-of-care environments respectively, while reagents and kits cover critical consumables such as buffers, enzymes, master mixes and primers and probes that underpin assay performance. Software and services-including data analysis software, maintenance and support, and training and consulting services-are increasingly integral to successful deployment and ongoing operational optimization.

End user differentiation spans diagnostic laboratories, hospitals, point of care testing sites and research institutes, with each segment exhibiting unique throughput, regulatory and staffing requirements that influence procurement decisions. Application-focused segmentation further clarifies clinical priorities, encompassing companion diagnostics, genetic testing, infectious disease and oncology. Within genetic testing, sub-specializations such as carrier screening, prenatal testing and rare disease diagnostics demand distinct assay sensitivity and reporting workflows, while infectious disease categories cover bacterial, parasitic and viral detection needs. Oncology applications concentrate on biomarker testing, minimal residual disease detection and mutation analysis, driving demand for high-sensitivity platforms and robust bioinformatics.

Explaining how regional regulatory frameworks, investment patterns and manufacturing capabilities create distinct adoption pathways across major global geographies

Regional dynamics shape investment priorities, regulatory approaches and commercial models across the Americas, Europe, Middle East & Africa, and Asia-Pacific, each presenting distinct opportunities and operational considerations. In the Americas, there is sustained demand for high-throughput laboratory systems and point-of-care capabilities driven by integrated healthcare networks and a mature reimbursement environment, while regulatory pathways emphasize rigorous validation and clinical utility demonstrations. This region also demonstrates strong private and public investment into pandemic preparedness and genomic surveillance initiatives, supporting broad uptake of diverse NAAT technologies.

The Europe, Middle East & Africa region presents a heterogeneous landscape: Western European markets often adopt advanced instrumentation and precision diagnostics, supported by structured regulatory frameworks and centralized laboratory networks, whereas emerging markets in the Middle East and Africa prioritize cost-effective, portable solutions and training to expand access. Cross-border regulatory harmonization and regional procurement programs can accelerate adoption but also require manufacturers to navigate varied compliance regimes and logistical challenges.

Asia-Pacific is characterized by rapid adoption of decentralized testing models, significant local manufacturing capacity and strong government-led initiatives to expand diagnostics infrastructure. Several markets in this region are investing heavily in domestic production, which can influence global supply chains and competitive dynamics. Across regions, differences in reimbursement, clinical practice, and public health priorities necessitate tailored market entry and commercialization strategies that align technology portfolios with local needs and regulatory expectations.

Examining strategic business models, partnership ecosystems and operational investments that position companies to capture value across instruments, reagents and data services

Company strategies in the nucleic acid amplification testing sphere reflect a balance between technological innovation, operational resilience and commercial scale. Leading organizations are investing in integrated portfolios that combine robust instrument platforms with proprietary reagents and data analytics capabilities to create recurring revenue streams and competitive differentiation. Simultaneously, some firms concentrate on modular or open-platform approaches that allow third-party reagents and assay development partners to accelerate adoption across diverse end-user settings.

Partnerships and collaborations are prevalent, spanning co-development with academic groups, licensing arrangements for assay chemistries, and strategic alliances with service providers to expand market reach. Business models that emphasize service contracts, training, and maintenance can deepen customer relationships and stabilize revenue over time. In parallel, firms are scaling manufacturing and supply chain processes, including investments in regional production capacity and quality systems to meet regulatory demands and to mitigate tariff exposure.

Organizational focus on data services and cloud-enabled software reflects recognition that actionable interpretation and workflow integration are as important as raw assay performance. Companies prioritizing regulatory expertise, customer support infrastructure and flexible commercialization options are better positioned to penetrate hospital systems, diagnostic laboratories and decentralized care settings, enabling sustained growth as testing paradigms evolve.

Providing prioritized strategic actions for technology development, supply chain diversification, regulatory engagement and service-led commercialization to drive sustainable growth

Industry leaders should adopt a multi-pronged strategy that aligns technology roadmaps with supply chain resilience and customer-centric commercialization. First, prioritize modular platform development that supports both centralized high-throughput needs and decentralized point-of-care deployment, enabling a single product family to serve multiple end-user requirements with shared consumables and validated workflows. This approach reduces complexity for customers and accelerates adoption across settings.

Second, diversify supply chains by qualifying alternative manufacturers for critical reagents and components, and by exploring regional manufacturing partnerships to mitigate tariff exposure and logistics risk. Coupling this with scenario-based procurement modeling will improve responsiveness to trade policy shifts. Third, expand offerings beyond hardware by embedding robust data analysis software, training and maintenance services that create recurring revenue and strengthen long-term customer relationships. Investing in intuitive user interfaces and integrated reporting will reduce the total cost of ownership for buyers.

Fourth, engage proactively with regulators and clinical stakeholders to streamline validation pathways and to demonstrate clinical utility through real-world evidence initiatives. Finally, cultivate strategic collaborations with academic and clinical partners to accelerate assay development for priority applications such as infectious disease surveillance, oncology biomarker testing and rare disease diagnostics, thereby enhancing competitive differentiation and adoption momentum.

Outlining a mixed-methods research approach combining expert interviews, technical review and scenario analysis to validate insights across the nucleic acid amplification testing value chain

The research methodology underpinning this analysis combined structured primary research, targeted secondary inquiry and rigorous validation to ensure relevance and accuracy. Primary research included in-depth interviews with clinical laboratory directors, hospital procurement officers, assay developers, and technology vendors to capture practical insights on adoption drivers, operational barriers and procurement dynamics. These qualitative inputs were supplemented by technical consultations with molecular biologists and bioinformatics specialists to assess assay performance trade-offs and integration challenges.

Secondary research involved a comprehensive review of peer-reviewed literature, regulatory guidance documents, patent filings, and publicly available product specifications to map technology capabilities and compliance requirements. Supply chain assessments incorporated trade data and supplier disclosures to evaluate manufacturing footprints and potential vulnerabilities. The analysis also applied scenario planning to test the sensitivity of commercialization strategies to variables such as tariff changes, regulatory timelines and shifts in clinical practice.

Findings were triangulated across sources and validated through follow-up discussions with subject matter experts. Care was taken to avoid proprietary vendor claims without corroboration, and methodological limitations related to rapidly changing policy environments and emerging technologies are noted to contextualize the conclusions and recommendations offered.

Summarizing the convergence of technological evolution, operational resilience and policy forces that will shape long-term adoption and value capture in nucleic acid amplification testing

In conclusion, nucleic acid amplification testing stands at a strategic inflection point where technological innovation, commercial strategy and policy dynamics intersect to determine future trajectories. The maturation of isothermal modalities alongside advanced PCR techniques, the proliferation of portable and benchtop platforms, and the integration of sophisticated data analysis tools collectively expand the range and settings for deployment. At the same time, evolving trade policies, regulatory expectations and regional manufacturing shifts require stakeholders to be deliberate in sourcing, validation and market entry decisions.

Organizations that successfully align product design with real-world workflow requirements, invest in supply chain resilience and prioritize service-oriented business models will be better equipped to capitalize on growing demand for rapid, accurate molecular diagnostics. Cross-sector collaboration among developers, clinicians and regulatory bodies will accelerate adoption and ensure that assays deliver meaningful clinical and public health value. By taking a disciplined, scenario-informed approach to strategy and execution, stakeholders can navigate near-term disruptions and position themselves for sustained leadership in the expanding NAAT ecosystem.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Nucleic Acid Amplification Testing Market, by Technology

  • 8.1. Isothermal Amplification
    • 8.1.1. Helicase Dependent Amplification
    • 8.1.2. Loop Mediated Amplification
    • 8.1.3. Nucleic Acid Sequence Based Amplification
    • 8.1.4. Strand Displacement Amplification
    • 8.1.5. Transcription Mediated Amplification
  • 8.2. Polymerase Chain Reaction
    • 8.2.1. Digital Polymerase Chain Reaction
    • 8.2.2. Real Time Polymerase Chain Reaction

9. Nucleic Acid Amplification Testing Market, by Product Type

  • 9.1. Instruments
    • 9.1.1. Benchtop Instruments
    • 9.1.2. Portable Instruments
  • 9.2. Reagents & Kits
    • 9.2.1. Buffers
    • 9.2.2. Enzymes
    • 9.2.3. Master Mixes
    • 9.2.4. Primers & Probes
  • 9.3. Software & Services
    • 9.3.1. Data Analysis Software
    • 9.3.2. Maintenance & Support
    • 9.3.3. Training & Consulting Services

10. Nucleic Acid Amplification Testing Market, by End User

  • 10.1. Diagnostic Laboratories
  • 10.2. Hospitals
  • 10.3. Point Of Care Testing
  • 10.4. Research Institutes

11. Nucleic Acid Amplification Testing Market, by Application

  • 11.1. Companion Diagnostics
  • 11.2. Genetic Testing
    • 11.2.1. Carrier Screening
    • 11.2.2. Prenatal Genetic Testing
    • 11.2.3. Rare Disease Diagnostics
  • 11.3. Infectious Disease
    • 11.3.1. Bacterial Infectious Disease
    • 11.3.2. Parasitic Infectious Disease
    • 11.3.3. Viral Infectious Disease
  • 11.4. Oncology
    • 11.4.1. Biomarker Testing
    • 11.4.2. Minimal Residual Disease Detection
    • 11.4.3. Mutation Analysis

12. Nucleic Acid Amplification Testing Market, by Region

  • 12.1. Americas
    • 12.1.1. North America
    • 12.1.2. Latin America
  • 12.2. Europe, Middle East & Africa
    • 12.2.1. Europe
    • 12.2.2. Middle East
    • 12.2.3. Africa
  • 12.3. Asia-Pacific

13. Nucleic Acid Amplification Testing Market, by Group

  • 13.1. ASEAN
  • 13.2. GCC
  • 13.3. European Union
  • 13.4. BRICS
  • 13.5. G7
  • 13.6. NATO

14. Nucleic Acid Amplification Testing Market, by Country

  • 14.1. United States
  • 14.2. Canada
  • 14.3. Mexico
  • 14.4. Brazil
  • 14.5. United Kingdom
  • 14.6. Germany
  • 14.7. France
  • 14.8. Russia
  • 14.9. Italy
  • 14.10. Spain
  • 14.11. China
  • 14.12. India
  • 14.13. Japan
  • 14.14. Australia
  • 14.15. South Korea

15. United States Nucleic Acid Amplification Testing Market

16. China Nucleic Acid Amplification Testing Market

17. Competitive Landscape

  • 17.1. Market Concentration Analysis, 2025
    • 17.1.1. Concentration Ratio (CR)
    • 17.1.2. Herfindahl Hirschman Index (HHI)
  • 17.2. Recent Developments & Impact Analysis, 2025
  • 17.3. Product Portfolio Analysis, 2025
  • 17.4. Benchmarking Analysis, 2025
  • 17.5. Abbott Laboratories
  • 17.6. Becton, Dickinson and Company
  • 17.7. BGI Genomics Co. Ltd.
  • 17.8. Bio-Rad Laboratories, Inc.
  • 17.9. bioMerieux SA
  • 17.10. Bruker Corporation
  • 17.11. Danaher Corporation
  • 17.12. Diasorin S.p.A.
  • 17.13. F. Hoffmann-La Roche AG
  • 17.14. Grifols, S.A.
  • 17.15. Hologic, Inc.
  • 17.16. Molbio Diagnostics Pvt. Ltd.
  • 17.17. Mylab Discovery Solutions
  • 17.18. Pfizer Inc
  • 17.19. QuidelOrtho Corporation
  • 17.20. Randox Laboratories Ltd
  • 17.21. Thermo Fisher Scientific Inc.

LIST OF FIGURES

  • FIGURE 1. GLOBAL NUCLEIC ACID AMPLIFICATION TESTING MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL NUCLEIC ACID AMPLIFICATION TESTING MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL NUCLEIC ACID AMPLIFICATION TESTING MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL NUCLEIC ACID AMPLIFICATION TESTING MARKET SIZE, BY TECHNOLOGY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL NUCLEIC ACID AMPLIFICATION TESTING MARKET SIZE, BY PRODUCT TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL NUCLEIC ACID AMPLIFICATION TESTING MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL NUCLEIC ACID AMPLIFICATION TESTING MARKET SIZE, BY APPLICATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL NUCLEIC ACID AMPLIFICATION TESTING MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL NUCLEIC ACID AMPLIFICATION TESTING MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL NUCLEIC ACID AMPLIFICATION TESTING MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. UNITED STATES NUCLEIC ACID AMPLIFICATION TESTING MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 12. CHINA NUCLEIC ACID AMPLIFICATION TESTING MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL NUCLEIC ACID AMPLIFICATION TESTING MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL NUCLEIC ACID AMPLIFICATION TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL NUCLEIC ACID AMPLIFICATION TESTING MARKET SIZE, BY ISOTHERMAL AMPLIFICATION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL NUCLEIC ACID AMPLIFICATION TESTING MARKET SIZE, BY ISOTHERMAL AMPLIFICATION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL NUCLEIC ACID AMPLIFICATION TESTING MARKET SIZE, BY ISOTHERMAL AMPLIFICATION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL NUCLEIC ACID AMPLIFICATION TESTING MARKET SIZE, BY ISOTHERMAL AMPLIFICATION, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL NUCLEIC ACID AMPLIFICATION TESTING MARKET SIZE, BY HELICASE DEPENDENT AMPLIFICATION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL NUCLEIC ACID AMPLIFICATION TESTING MARKET SIZE, BY HELICASE DEPENDENT AMPLIFICATION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL NUCLEIC ACID AMPLIFICATION TESTING MARKET SIZE, BY HELICASE DEPENDENT AMPLIFICATION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL NUCLEIC ACID AMPLIFICATION TESTING MARKET SIZE, BY LOOP MEDIATED AMPLIFICATION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL NUCLEIC ACID AMPLIFICATION TESTING MARKET SIZE, BY LOOP MEDIATED AMPLIFICATION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL NUCLEIC ACID AMPLIFICATION TESTING MARKET SIZE, BY LOOP MEDIATED AMPLIFICATION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL NUCLEIC ACID AMPLIFICATION TESTING MARKET SIZE, BY NUCLEIC ACID SEQUENCE BASED AMPLIFICATION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL NUCLEIC ACID AMPLIFICATION TESTING MARKET SIZE, BY NUCLEIC ACID SEQUENCE BASED AMPLIFICATION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL NUCLEIC ACID AMPLIFICATION TESTING MARKET SIZE, BY NUCLEIC ACID SEQUENCE BASED AMPLIFICATION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL NUCLEIC ACID AMPLIFICATION TESTING MARKET SIZE, BY STRAND DISPLACEMENT AMPLIFICATION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL NUCLEIC ACID AMPLIFICATION TESTING MARKET SIZE, BY STRAND DISPLACEMENT AMPLIFICATION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL NUCLEIC ACID AMPLIFICATION TESTING MARKET SIZE, BY STRAND DISPLACEMENT AMPLIFICATION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL NUCLEIC ACID AMPLIFICATION TESTING MARKET SIZE, BY TRANSCRIPTION MEDIATED AMPLIFICATION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL NUCLEIC ACID AMPLIFICATION TESTING MARKET SIZE, BY TRANSCRIPTION MEDIATED AMPLIFICATION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL NUCLEIC ACID AMPLIFICATION TESTING MARKET SIZE, BY TRANSCRIPTION MEDIATED AMPLIFICATION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL NUCLEIC ACID AMPLIFICATION TESTING MARKET SIZE, BY POLYMERASE CHAIN REACTION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL NUCLEIC ACID AMPLIFICATION TESTING MARKET SIZE, BY POLYMERASE CHAIN REACTION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL NUCLEIC ACID AMPLIFICATION TESTING MARKET SIZE, BY POLYMERASE CHAIN REACTION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL NUCLEIC ACID AMPLIFICATION TESTING MARKET SIZE, BY POLYMERASE CHAIN REACTION, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL NUCLEIC ACID AMPLIFICATION TESTING MARKET SIZE, BY DIGITAL POLYMERASE CHAIN REACTION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL NUCLEIC ACID AMPLIFICATION TESTING MARKET SIZE, BY DIGITAL POLYMERASE CHAIN REACTION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL NUCLEIC ACID AMPLIFICATION TESTING MARKET SIZE, BY DIGITAL POLYMERASE CHAIN REACTION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL NUCLEIC ACID AMPLIFICATION TESTING MARKET SIZE, BY REAL TIME POLYMERASE CHAIN REACTION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL NUCLEIC ACID AMPLIFICATION TESTING MARKET SIZE, BY REAL TIME POLYMERASE CHAIN REACTION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL NUCLEIC ACID AMPLIFICATION TESTING MARKET SIZE, BY REAL TIME POLYMERASE CHAIN REACTION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL NUCLEIC ACID AMPLIFICATION TESTING MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL NUCLEIC ACID AMPLIFICATION TESTING MARKET SIZE, BY INSTRUMENTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL NUCLEIC ACID AMPLIFICATION TESTING MARKET SIZE, BY INSTRUMENTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL NUCLEIC ACID AMPLIFICATION TESTING MARKET SIZE, BY INSTRUMENTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL NUCLEIC ACID AMPLIFICATION TESTING MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL NUCLEIC ACID AMPLIFICATION TESTING MARKET SIZE, BY BENCHTOP INSTRUMENTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL NUCLEIC ACID AMPLIFICATION TESTING MARKET SIZE, BY BENCHTOP INSTRUMENTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL NUCLEIC ACID AMPLIFICATION TESTING MARKET SIZE, BY BENCHTOP INSTRUMENTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL NUCLEIC ACID AMPLIFICATION TESTING MARKET SIZE, BY PORTABLE INSTRUMENTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL NUCLEIC ACID AMPLIFICATION TESTING MARKET SIZE, BY PORTABLE INSTRUMENTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL NUCLEIC ACID AMPLIFICATION TESTING MARKET SIZE, BY PORTABLE INSTRUMENTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL NUCLEIC ACID AMPLIFICATION TESTING MARKET SIZE, BY REAGENTS & KITS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL NUCLEIC ACID AMPLIFICATION TESTING MARKET SIZE, BY REAGENTS & KITS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL NUCLEIC ACID AMPLIFICATION TESTING MARKET SIZE, BY REAGENTS & KITS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL NUCLEIC ACID AMPLIFICATION TESTING MARKET SIZE, BY REAGENTS & KITS, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL NUCLEIC ACID AMPLIFICATION TESTING MARKET SIZE, BY BUFFERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL NUCLEIC ACID AMPLIFICATION TESTING MARKET SIZE, BY BUFFERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL NUCLEIC ACID AMPLIFICATION TESTING MARKET SIZE, BY BUFFERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL NUCLEIC ACID AMPLIFICATION TESTING MARKET SIZE, BY ENZYMES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL NUCLEIC ACID AMPLIFICATION TESTING MARKET SIZE, BY ENZYMES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL NUCLEIC ACID AMPLIFICATION TESTING MARKET SIZE, BY ENZYMES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL NUCLEIC ACID AMPLIFICATION TESTING MARKET SIZE, BY MASTER MIXES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL NUCLEIC ACID AMPLIFICATION TESTING MARKET SIZE, BY MASTER MIXES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL NUCLEIC ACID AMPLIFICATION TESTING MARKET SIZE, BY MASTER MIXES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL NUCLEIC ACID AMPLIFICATION TESTING MARKET SIZE, BY PRIMERS & PROBES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL NUCLEIC ACID AMPLIFICATION TESTING MARKET SIZE, BY PRIMERS & PROBES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL NUCLEIC ACID AMPLIFICATION TESTING MARKET SIZE, BY PRIMERS & PROBES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL NUCLEIC ACID AMPLIFICATION TESTING MARKET SIZE, BY SOFTWARE & SERVICES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL NUCLEIC ACID AMPLIFICATION TESTING MARKET SIZE, BY SOFTWARE & SERVICES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL NUCLEIC ACID AMPLIFICATION TESTING MARKET SIZE, BY SOFTWARE & SERVICES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL NUCLEIC ACID AMPLIFICATION TESTING MARKET SIZE, BY SOFTWARE & SERVICES, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL NUCLEIC ACID AMPLIFICATION TESTING MARKET SIZE, BY DATA ANALYSIS SOFTWARE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL NUCLEIC ACID AMPLIFICATION TESTING MARKET SIZE, BY DATA ANALYSIS SOFTWARE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL NUCLEIC ACID AMPLIFICATION TESTING MARKET SIZE, BY DATA ANALYSIS SOFTWARE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL NUCLEIC ACID AMPLIFICATION TESTING MARKET SIZE, BY MAINTENANCE & SUPPORT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL NUCLEIC ACID AMPLIFICATION TESTING MARKET SIZE, BY MAINTENANCE & SUPPORT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL NUCLEIC ACID AMPLIFICATION TESTING MARKET SIZE, BY MAINTENANCE & SUPPORT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL NUCLEIC ACID AMPLIFICATION TESTING MARKET SIZE, BY TRAINING & CONSULTING SERVICES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL NUCLEIC ACID AMPLIFICATION TESTING MARKET SIZE, BY TRAINING & CONSULTING SERVICES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL NUCLEIC ACID AMPLIFICATION TESTING MARKET SIZE, BY TRAINING & CONSULTING SERVICES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL NUCLEIC ACID AMPLIFICATION TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL NUCLEIC ACID AMPLIFICATION TESTING MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL NUCLEIC ACID AMPLIFICATION TESTING MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL NUCLEIC ACID AMPLIFICATION TESTING MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL NUCLEIC ACID AMPLIFICATION TESTING MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL NUCLEIC ACID AMPLIFICATION TESTING MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL NUCLEIC ACID AMPLIFICATION TESTING MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 79. GLOBAL NUCLEIC ACID AMPLIFICATION TESTING MARKET SIZE, BY POINT OF CARE TESTING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 80. GLOBAL NUCLEIC ACID AMPLIFICATION TESTING MARKET SIZE, BY POINT OF CARE TESTING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 81. GLOBAL NUCLEIC ACID AMPLIFICATION TESTING MARKET SIZE, BY POINT OF CARE TESTING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 82. GLOBAL NUCLEIC ACID AMPLIFICATION TESTING MARKET SIZE, BY RESEARCH INSTITUTES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 83. GLOBAL NUCLEIC ACID AMPLIFICATION TESTING MARKET SIZE, BY RESEARCH INSTITUTES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 84. GLOBAL NUCLEIC ACID AMPLIFICATION TESTING MARKET SIZE, BY RESEARCH INSTITUTES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 85. GLOBAL NUCLEIC ACID AMPLIFICATION TESTING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 86. GLOBAL NUCLEIC ACID AMPLIFICATION TESTING MARKET SIZE, BY COMPANION DIAGNOSTICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 87. GLOBAL NUCLEIC ACID AMPLIFICATION TESTING MARKET SIZE, BY COMPANION DIAGNOSTICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 88. GLOBAL NUCLEIC ACID AMPLIFICATION TESTING MARKET SIZE, BY COMPANION DIAGNOSTICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 89. GLOBAL NUCLEIC ACID AMPLIFICATION TESTING MARKET SIZE, BY GENETIC TESTING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 90. GLOBAL NUCLEIC ACID AMPLIFICATION TESTING MARKET SIZE, BY GENETIC TESTING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 91. GLOBAL NUCLEIC ACID AMPLIFICATION TESTING MARKET SIZE, BY GENETIC TESTING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 92. GLOBAL NUCLEIC ACID AMPLIFICATION TESTING MARKET SIZE, BY GENETIC TESTING, 2018-2032 (USD MILLION)
  • TABLE 93. GLOBAL NUCLEIC ACID AMPLIFICATION TESTING MARKET SIZE, BY CARRIER SCREENING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 94. GLOBAL NUCLEIC ACID AMPLIFICATION TESTING MARKET SIZE, BY CARRIER SCREENING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 95. GLOBAL NUCLEIC ACID AMPLIFICATION TESTING MARKET SIZE, BY CARRIER SCREENING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 96. GLOBAL NUCLEIC ACID AMPLIFICATION TESTING MARKET SIZE, BY PRENATAL GENETIC TESTING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 97. GLOBAL NUCLEIC ACID AMPLIFICATION TESTING MARKET SIZE, BY PRENATAL GENETIC TESTING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 98. GLOBAL NUCLEIC ACID AMPLIFICATION TESTING MARKET SIZE, BY PRENATAL GENETIC TESTING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 99. GLOBAL NUCLEIC ACID AMPLIFICATION TESTING MARKET SIZE, BY RARE DISEASE DIAGNOSTICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 100. GLOBAL NUCLEIC ACID AMPLIFICATION TESTING MARKET SIZE, BY RARE DISEASE DIAGNOSTICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 101. GLOBAL NUCLEIC ACID AMPLIFICATION TESTING MARKET SIZE, BY RARE DISEASE DIAGNOSTICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 102. GLOBAL NUCLEIC ACID AMPLIFICATION TESTING MARKET SIZE, BY INFECTIOUS DISEASE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 103. GLOBAL NUCLEIC ACID AMPLIFICATION TESTING MARKET SIZE, BY INFECTIOUS DISEASE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 104. GLOBAL NUCLEIC ACID AMPLIFICATION TESTING MARKET SIZE, BY INFECTIOUS DISEASE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 105. GLOBAL NUCLEIC ACID AMPLIFICATION TESTING MARKET SIZE, BY INFECTIOUS DISEASE, 2018-2032 (USD MILLION)
  • TABLE 106. GLOBAL NUCLEIC ACID AMPLIFICATION TESTING MARKET SIZE, BY BACTERIAL INFECTIOUS DISEASE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 107. GLOBAL NUCLEIC ACID AMPLIFICATION TESTING MARKET SIZE, BY BACTERIAL INFECTIOUS DISEASE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 108. GLOBAL NUCLEIC ACID AMPLIFICATION TESTING MARKET SIZE, BY BACTERIAL INFECTIOUS DISEASE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 109. GLOBAL NUCLEIC ACID AMPLIFICATION TESTING MARKET SIZE, BY PARASITIC INFECTIOUS DISEASE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 110. GLOBAL NUCLEIC ACID AMPLIFICATION TESTING MARKET SIZE, BY PARASITIC INFECTIOUS DISEASE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 111. GLOBAL NUCLEIC ACID AMPLIFICATION TESTING MARKET SIZE, BY PARASITIC INFECTIOUS DISEASE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 112. GLOBAL NUCLEIC ACID AMPLIFICATION TESTING MARKET SIZE, BY VIRAL INFECTIOUS DISEASE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 113. GLOBAL NUCLEIC ACID AMPLIFICATION TESTING MARKET SIZE, BY VIRAL INFECTIOUS DISEASE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 114. GLOBAL NUCLEIC ACID AMPLIFICATION TESTING MARKET SIZE, BY VIRAL INFECTIOUS DISEASE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 115. GLOBAL NUCLEIC ACID AMPLIFICATION TESTING MARKET SIZE, BY ONCOLOGY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 116. GLOBAL NUCLEIC ACID AMPLIFICATION TESTING MARKET SIZE, BY ONCOLOGY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 117. GLOBAL NUCLEIC ACID AMPLIFICATION TESTING MARKET SIZE, BY ONCOLOGY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 118. GLOBAL NUCLEIC ACID AMPLIFICATION TESTING MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 119. GLOBAL NUCLEIC ACID AMPLIFICATION TESTING MARKET SIZE, BY BIOMARKER TESTING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 120. GLOBAL NUCLEIC ACID AMPLIFICATION TESTING MARKET SIZE, BY BIOMARKER TESTING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 121. GLOBAL NUCLEIC ACID AMPLIFICATION TESTING MARKET SIZE, BY BIOMARKER TESTING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 122. GLOBAL NUCLEIC ACID AMPLIFICATION TESTING MARKET SIZE, BY MINIMAL RESIDUAL DISEASE DETECTION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 123. GLOBAL NUCLEIC ACID AMPLIFICATION TESTING MARKET SIZE, BY MINIMAL RESIDUAL DISEASE DETECTION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 124. GLOBAL NUCLEIC ACID AMPLIFICATION TESTING MARKET SIZE, BY MINIMAL RESIDUAL DISEASE DETECTION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 125. GLOBAL NUCLEIC ACID AMPLIFICATION TESTING MARKET SIZE, BY MUTATION ANALYSIS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 126. GLOBAL NUCLEIC ACID AMPLIFICATION TESTING MARKET SIZE, BY MUTATION ANALYSIS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 127. GLOBAL NUCLEIC ACID AMPLIFICATION TESTING MARKET SIZE, BY MUTATION ANALYSIS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 128. GLOBAL NUCLEIC ACID AMPLIFICATION TESTING MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 129. AMERICAS NUCLEIC ACID AMPLIFICATION TESTING MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 130. AMERICAS NUCLEIC ACID AMPLIFICATION TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 131. AMERICAS NUCLEIC ACID AMPLIFICATION TESTING MARKET SIZE, BY ISOTHERMAL AMPLIFICATION, 2018-2032 (USD MILLION)
  • TABLE 132. AMERICAS NUCLEIC ACID AMPLIFICATION TESTING MARKET SIZE, BY POLYMERASE CHAIN REACTION, 2018-2032 (USD MILLION)
  • TABLE 133. AMERICAS NUCLEIC ACID AMPLIFICATION TESTING MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 134. AMERICAS NUCLEIC ACID AMPLIFICATION TESTING MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 135. AMERICAS NUCLEIC ACID AMPLIFICATION TESTING MARKET SIZE, BY REAGENTS & KITS, 2018-2032 (USD MILLION)
  • TABLE 136. AMERICAS NUCLEIC ACID AMPLIFICATION TESTING MARKET SIZE, BY SOFTWARE & SERVICES, 2018-2032 (USD MILLION)
  • TABLE 137. AMERICAS NUCLEIC ACID AMPLIFICATION TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 138. AMERICAS NUCLEIC ACID AMPLIFICATION TESTING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 139. AMERICAS NUCLEIC ACID AMPLIFICATION TESTING MARKET SIZE, BY GENETIC TESTING, 2018-2032 (USD MILLION)
  • TABLE 140. AMERICAS NUCLEIC ACID AMPLIFICATION TESTING MARKET SIZE, BY INFECTIOUS DISEASE, 2018-2032 (USD MILLION)
  • TABLE 141. AMERICAS NUCLEIC ACID AMPLIFICATION TESTING MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 142. NORTH AMERICA NUCLEIC ACID AMPLIFICATION TESTING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 143. NORTH AMERICA NUCLEIC ACID AMPLIFICATION TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 144. NORTH AMERICA NUCLEIC ACID AMPLIFICATION TESTING MARKET SIZE, BY ISOTHERMAL AMPLIFICATION, 2018-2032 (USD MILLION)
  • TABLE 145. NORTH AMERICA NUCLEIC ACID AMPLIFICATION TESTING MARKET SIZE, BY POLYMERASE CHAIN REACTION, 2018-2032 (USD MILLION)
  • TABLE 146. NORTH AMERICA NUCLEIC ACID AMPLIFICATION TESTING MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 147. NORTH AMERICA NUCLEIC ACID AMPLIFICATION TESTING MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 148. NORTH AMERICA NUCLEIC ACID AMPLIFICATION TESTING MARKET SIZE, BY REAGENTS & KITS, 2018-2032 (USD MILLION)
  • TABLE 149. NORTH AMERICA NUCLEIC ACID AMPLIFICATION TESTING MARKET SIZE, BY SOFTWARE & SERVICES, 2018-2032 (USD MILLION)
  • TABLE 150. NORTH AMERICA NUCLEIC ACID AMPLIFICATION TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 151. NORTH AMERICA NUCLEIC ACID AMPLIFICATION TESTING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 152. NORTH AMERICA NUCLEIC ACID AMPLIFICATION TESTING MARKET SIZE, BY GENETIC TESTING, 2018-2032 (USD MILLION)
  • TABLE 153. NORTH AMERICA NUCLEIC ACID AMPLIFICATION TESTING MARKET SIZE, BY INFECTIOUS DISEASE, 2018-2032 (USD MILLION)
  • TABLE 154. NORTH AMERICA NUCLEIC ACID AMPLIFICATION TESTING MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 155. LATIN AMERICA NUCLEIC ACID AMPLIFICATION TESTING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 156. LATIN AMERICA NUCLEIC ACID AMPLIFICATION TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 157. LATIN AMERICA NUCLEIC ACID AMPLIFICATION TESTING MARKET SIZE, BY ISOTHERMAL AMPLIFICATION, 2018-2032 (USD MILLION)
  • TABLE 158. LATIN AMERICA NUCLEIC ACID AMPLIFICATION TESTING MARKET SIZE, BY POLYMERASE CHAIN REACTION, 2018-2032 (USD MILLION)
  • TABLE 159. LATIN AMERICA NUCLEIC ACID AMPLIFICATION TESTING MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 160. LATIN AMERICA NUCLEIC ACID AMPLIFICATION TESTING MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 161. LATIN AMERICA NUCLEIC ACID AMPLIFICATION TESTING MARKET SIZE, BY REAGENTS & KITS, 2018-2032 (USD MILLION)
  • TABLE 162. LATIN AMERICA NUCLEIC ACID AMPLIFICATION TESTING MARKET SIZE, BY SOFTWARE & SERVICES, 2018-2032 (USD MILLION)
  • TABLE 163. LATIN AMERICA NUCLEIC ACID AMPLIFICATION TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 164. LATIN AMERICA NUCLEIC ACID AMPLIFICATION TESTING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 165. LATIN AMERICA NUCLEIC ACID AMPLIFICATION TESTING MARKET SIZE, BY GENETIC TESTING, 2018-2032 (USD MILLION)
  • TABLE 166. LATIN AMERICA NUCLEIC ACID AMPLIFICATION TESTING MARKET SIZE, BY INFECTIOUS DISEASE, 2018-2032 (USD MILLION)
  • TABLE 167. LATIN AMERICA NUCLEIC ACID AMPLIFICATION TESTING MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 168. EUROPE, MIDDLE EAST & AFRICA NUCLEIC ACID AMPLIFICATION TESTING MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 169. EUROPE, MIDDLE EAST & AFRICA NUCLEIC ACID AMPLIFICATION TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 170. EUROPE, MIDDLE EAST & AFRICA NUCLEIC ACID AMPLIFICATION TESTING MARKET SIZE, BY ISOTHERMAL AMPLIFICATION, 2018-2032 (USD MILLION)
  • TABLE 171. EUROPE, MIDDLE EAST & AFRICA NUCLEIC ACID AMPLIFICATION TESTING MARKET SIZE, BY POLYMERASE CHAIN REACTION, 2018-2032 (USD MILLION)
  • TABLE 172. EUROPE, MIDDLE EAST & AFRICA NUCLEIC ACID AMPLIFICATION TESTING MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 173. EUROPE, MIDDLE EAST & AFRICA NUCLEIC ACID AMPLIFICATION TESTING MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 174. EUROPE, MIDDLE EAST & AFRICA NUCLEIC ACID AMPLIFICATION TESTING MARKET SIZE, BY REAGENTS & KITS, 2018-2032 (USD MILLION)
  • TABLE 175. EUROPE, MIDDLE EAST & AFRICA NUCLEIC ACID AMPLIFICATION TESTING MARKET SIZE, BY SOFTWARE & SERVICES, 2018-2032 (USD MILLION)
  • TABLE 176. EUROPE, MIDDLE EAST & AFRICA NUCLEIC ACID AMPLIFICATION TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 177. EUROPE, MIDDLE EAST & AFRICA NUCLEIC ACID AMPLIFICATION TESTING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 178. EUROPE, MIDDLE EAST & AFRICA NUCLEIC ACID AMPLIFICATION TESTING MARKET SIZE, BY GENETIC TESTING, 2018-2032 (USD MILLION)
  • TABLE 179. EUROPE, MIDDLE EAST & AFRICA NUCLEIC ACID AMPLIFICATION TESTING MARKET SIZE, BY INFECTIOUS DISEASE, 2018-2032 (USD MILLION)
  • TABLE 180. EUROPE, MIDDLE EAST & AFRICA NUCLEIC ACID AMPLIFICATION TESTING MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 181. EUROPE NUCLEIC ACID AMPLIFICATION TESTING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 182. EUROPE NUCLEIC ACID AMPLIFICATION TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 183. EUROPE NUCLEIC ACID AMPLIFICATION TESTING MARKET SIZE, BY ISOTHERMAL AMPLIFICATION, 2018-2032 (USD MILLION)
  • TABLE 184. EUROPE NUCLEIC ACID AMPLIFICATION TESTING MARKET SIZE, BY POLYMERASE CHAIN REACTION, 2018-2032 (USD MILLION)
  • TABLE 185. EUROPE NUCLEIC ACID AMPLIFICATION TESTING MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 186. EUROPE NUCLEIC ACID AMPLIFICATION TESTING MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 187. EUROPE NUCLEIC ACID AMPLIFICATION TESTING MARKET SIZE, BY REAGENTS & KITS, 2018-2032 (USD MILLION)
  • TABLE 188. EUROPE NUCLEIC ACID AMPLIFICATION TESTING MARKET SIZE, BY SOFTWARE & SERVICES, 2018-2032 (USD MILLION)
  • TABLE 189. EUROPE NUCLEIC ACID AMPLIFICATION TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 190. EUROPE NUCLEIC ACID AMPLIFICATION TESTING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 191. EUROPE NUCLEIC ACID AMPLIFICATION TESTING MARKET SIZE, BY GENETIC TESTING, 2018-2032 (USD MILLION)
  • TABLE 192. EUROPE NUCLEIC ACID AMPLIFICATION TESTING MARKET SIZE, BY INFECTIOUS DISEASE, 2018-2032 (USD MILLION)
  • TABLE 193. EUROPE NUCLEIC ACID AMPLIFICATION TESTING MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 194. MIDDLE EAST NUCLEIC ACID AMPLIFICATION TESTING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 195. MIDDLE EAST NUCLEIC ACID AMPLIFICATION TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 196. MIDDLE EAST NUCLEIC ACID AMPLIFICATION TESTING MARKET SIZE, BY ISOTHERMAL AMPLIFICATION, 2018-2032 (USD MILLION)
  • TABLE 197. MIDDLE EAST NUCLEIC ACID AMPLIFICATION TESTING MARKET SIZE, BY POLYMERASE CHAIN REACTION, 2018-2032 (USD MILLION)
  • TABLE 198. MIDDLE EAST NUCLEIC ACID AMPLIFICATION TESTING MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 199. MIDDLE EAST NUCLEIC ACID AMPLIFICATION TESTING MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 200. MIDDLE EAST NUCLEIC ACID AMPLIFICATION TESTING MARKET SIZE, BY REAGENTS & KITS, 2018-2032 (USD MILLION)
  • TABLE 201. MIDDLE EAST NUCLEIC ACID AMPLIFICATION TESTING MARKET SIZE, BY SOFTWARE & SERVICES, 2018-2032 (USD MILLION)
  • TABLE 202. MIDDLE EAST NUCLEIC ACID AMPLIFICATION TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 203. MIDDLE EAST NUCLEIC ACID AMPLIFICATION TESTING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 204. MIDDLE EAST NUCLEIC ACID AMPLIFICATION TESTING MARKET SIZE, BY GENETIC TESTING, 2018-2032 (USD MILLION)
  • TABLE 205. MIDDLE EAST NUCLEIC ACID AMPLIFICATION TESTING MARKET SIZE, BY INFECTIOUS DISEASE, 2018-2032 (USD MILLION)
  • TABLE 206. MIDDLE EAST NUCLEIC ACID AMPLIFICATION TESTING MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 207. AFRICA NUCLEIC ACID AMPLIFICATION TESTING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 208. AFRICA NUCLEIC ACID AMPLIFICATION TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 209. AFRICA NUCLEIC ACID AMPLIFICATION TESTING MARKET SIZE, BY ISOTHERMAL AMPLIFICATION, 2018-2032 (USD MILLION)
  • TABLE 210. AFRICA NUCLEIC ACID AMPLIFICATION TESTING MARKET SIZE, BY POLYMERASE CHAIN REACTION, 2018-2032 (USD MILLION)
  • TABLE 211. AFRICA NUCLEIC ACID AMPLIFICATION TESTING MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 212. AFRICA NUCLEIC ACID AMPLIFICATION TESTING MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 213. AFRICA NUCLEIC ACID AMPLIFICATION TESTING MARKET SIZE, BY REAGENTS & KITS, 2018-2032 (USD MILLION)
  • TABLE 214. AFRICA NUCLEIC ACID AMPLIFICATION TESTING MARKET SIZE, BY SOFTWARE & SERVICES, 2018-2032 (USD MILLION)
  • TABLE 215. AFRICA NUCLEIC ACID AMPLIFICATION TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 216. AFRICA NUCLEIC ACID AMPLIFICATION TESTING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 217. AFRICA NUCLEIC ACID AMPLIFICATION TESTING MARKET SIZE, BY GENETIC TESTING, 2018-2032 (USD MILLION)
  • TABLE 218. AFRICA NUCLEIC ACID AMPLIFICATION TESTING MARKET SIZE, BY INFECTIOUS DISEASE, 2018-2032 (USD MILLION)
  • TABLE 219. AFRICA NUCLEIC ACID AMPLIFICATION TESTING MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 220. ASIA-PACIFIC NUCLEIC ACID AMPLIFICATION TESTING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 221. ASIA-PACIFIC NUCLEIC ACID AMPLIFICATION TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 222. ASIA-PACIFIC NUCLEIC ACID AMPLIFICATION TESTING MARKET SIZE, BY ISOTHERMAL AMPLIFICATION, 2018-2032 (USD MILLION)
  • TABLE 223. ASIA-PACIFIC NUCLEIC ACID AMPLIFICATION TESTING MARKET SIZE, BY POLYMERASE CHAIN REACTION, 2018-2032 (USD MILLION)
  • TABLE 224. ASIA-PACIFIC NUCLEIC ACID AMPLIFICATION TESTING MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 225. ASIA-PACIFIC NUCLEIC ACID AMPLIFICATION TESTING MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 226. ASIA-PACIFIC NUCLEIC ACID AMPLIFICATION TESTING MARKET SIZE, BY REAGENTS & KITS, 2018-2032 (USD MILLION)
  • TABLE 227. ASIA-PACIFIC NUCLEIC ACID AMPLIFICATION TESTING MARKET SIZE, BY SOFTWARE & SERVICES, 2018-2032 (USD MILLION)
  • TABLE 228. ASIA-PACIFIC NUCLEIC ACID AMPLIFICATION TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 229. ASIA-PACIFIC NUCLEIC ACID AMPLIFICATION TESTING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 230. ASIA-PACIFIC NUCLEIC ACID AMPLIFICATION TESTING MARKET SIZE, BY GENETIC TESTING, 2018-2032 (USD MILLION)
  • TABLE 231. ASIA-PACIFIC NUCLEIC ACID AMPLIFICATION TESTING MARKET SIZE, BY INFECTIOUS DISEASE, 2018-2032 (USD MILLION)
  • TABLE 232. ASIA-PACIFIC NUCLEIC ACID AMPLIFICATION TESTING MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 233. GLOBAL NUCLEIC ACID AMPLIFICATION TESTING MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 234. ASEAN NUCLEIC ACID AMPLIFICATION TESTING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 235. ASEAN NUCLEIC ACID AMPLIFICATION TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 236. ASEAN NUCLEIC ACID AMPLIFICATION TESTING MARKET SIZE, BY ISOTHERMAL AMPLIFICATION, 2018-2032 (USD MILLION)
  • TABLE 237. ASEAN NUCLEIC ACID AMPLIFICATION TESTING MARKET SIZE, BY POLYMERASE CHAIN REACTION, 2018-2032 (USD MILLION)
  • TABLE 238. ASEAN NUCLEIC ACID AMPLIFICATION TESTING MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 239. ASEAN NUCLEIC ACID AMPLIFICATION TESTING MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 240. ASEAN NUCLEIC ACID AMPLIFICATION TESTING MARKET SIZE, BY REAGENTS & KITS, 2018-2032 (USD MILLION)
  • TABLE 241. ASEAN NUCLEIC ACID AMPLIFICATION TESTING MARKET SIZE, BY SOFTWARE & SERVICES, 2018-2032 (USD MILLION)
  • TABLE 242. ASEAN NUCLEIC ACID AMPLIFICATION TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 243. ASEAN NUCLEIC ACID AMPLIFICATION TESTING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 244. ASEAN NUCLEIC ACID AMPLIFICATION TESTING MARKET SIZE, BY GENETIC TESTING, 2018-2032 (USD MILLION)
  • TABLE 245. ASEAN NUCLEIC ACID AMPLIFICATION TESTING MARKET SIZE, BY INFECTIOUS DISEASE, 2018-2032 (USD MILLION)
  • TABLE 246. ASEAN NUCLEIC ACID AMPLIFICATION TESTING MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 247. GCC NUCLEIC ACID AMPLIFICATION TESTING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 248. GCC NUCLEIC ACID AMPLIFICATION TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 249. GCC NUCLEIC ACID AMPLIFICATION TESTING MARKET SIZE, BY ISOTHERMAL AMPLIFICATION, 2018-2032 (USD MILLION)
  • TABLE 250. GCC NUCLEIC ACID AMPLIFICATION TESTING MARKET SIZE, BY POLYMERASE CHAIN REACTION, 2018-2032 (USD MILLION)
  • TABLE 251. GCC NUCLEIC ACID AMPLIFICATION TESTING MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 252. GCC NUCLEIC ACID AMPLIFICATION TESTING MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 253. GCC NUCLEIC ACID AMPLIFICATION TESTING MARKET SIZE, BY REAGENTS & KITS, 2018-2032 (USD MILLION)
  • TABLE 254. GCC NUCLEIC ACID AMPLIFICATION TESTING MARKET SIZE, BY SOFTWARE & SERVICES, 2018-2032 (USD MILLION)
  • TABLE 255. GCC NUCLEIC ACID AMPLIFICATION TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 256. GCC NUCLEIC ACID AMPLIFICATION TESTING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 257. GCC NUCLEIC ACID AMPLIFICATION TESTING MARKET SIZE, BY GENETIC TESTING, 2018-2032 (USD MILLION)
  • TABLE 258. GCC NUCLEIC ACID AMPLIFICATION TESTING MARKET SIZE, BY INFECTIOUS DISEASE, 2018-2032 (USD MILLION)
  • TABLE 259. GCC NUCLEIC ACID AMPLIFICATION TESTING MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 260. EUROPEAN UNION NUCLEIC ACID AMPLIFICATION TESTING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 261. EUROPEAN UNION NUCLEIC ACID AMPLIFICATION TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 262. EUROPEAN UNION NUCLEIC ACID AMPLIFICATION TESTING MARKET SIZE, BY ISOTHERMAL AMPLIFICATION, 2018-2032 (USD MILLION)
  • TABLE 263. EUROPEAN UNION NUCLEIC ACID AMPLIFICATION TESTING MARKET SIZE, BY POLYMERASE CHAIN REACTION, 2018-2032 (USD MILLION)
  • TABLE 264. EUROPEAN UNION NUCLEIC ACID AMPLIFICATION TESTING MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 265. EUROPEAN UNION NUCLEIC ACID AMPLIFICATION TESTING MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 266. EUROPEAN UNION NUCLEIC ACID AMPLIFICATION TESTING MARKET SIZE, BY REAGENTS & KITS, 2018-2032 (USD MILLION)
  • TABLE 267. EUROPEAN UNION NUCLEIC ACID AMPLIFICATION TESTING MARKET SIZE, BY SOFTWARE & SERVICES, 2018-2032 (USD MILLION)
  • TABLE 268. EUROPEAN UNION NUCLEIC ACID AMPLIFICATION TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 269. EUROPEAN UNION NUCLEIC ACID AMPLIFICATION TESTING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 270. EUROPEAN UNION NUCLEIC ACID AMPLIFICATION TESTING MARKET SIZE, BY GENETIC TESTING, 2018-2032 (USD MILLION)
  • TABLE 271. EUROPEAN UNION NUCLEIC ACID AMPLIFICATION TESTING MARKET SIZE, BY INFECTIOUS DISEASE, 2018-2032 (USD MILLION)
  • TABLE 272. EUROPEAN UNION NUCLEIC ACID AMPLIFICATION TESTING MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 273. BRICS NUCLEIC ACID AMPLIFICATION TESTING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 274. BRICS NUCLEIC ACID AMPLIFICATION TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 275. BRICS NUCLEIC ACID AMPLIFICATION TESTING MARKET SIZE, BY ISOTHERMAL AMPLIFICATION, 2018-2032 (USD MILLION)
  • TABLE 276. BRICS NUCLEIC ACID AMPLIFICATION TESTING MARKET SIZE, BY P